Total Payments
$12,732
2024 Payments
$3,182
Companies
65
Transactions
792
Medicare Patients
2,678
Medicare Billing
$765,556
Payment Breakdown by Category
Food & Beverage$12,588 (98.9%)
Education$144.38 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,588 | 780 | 98.9% |
| Education | $144.38 | 12 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,281 | 95 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,010 | 52 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $838.03 | 64 | $0 (2024) |
| Genentech USA, Inc. | $799.21 | 56 | $0 (2024) |
| Janssen Biotech, Inc. | $795.34 | 47 | $0 (2024) |
| PFIZER INC. | $687.20 | 72 | $0 (2024) |
| Merck Sharp & Dohme LLC | $555.54 | 29 | $0 (2024) |
| Exelixis Inc. | $470.47 | 27 | $0 (2024) |
| Seagen Inc. | $439.39 | 30 | $0 (2023) |
| Incyte Corporation | $424.15 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,182 | 160 | Novartis Pharmaceuticals Corporation ($320.93) |
| 2023 | $3,117 | 149 | Novartis Pharmaceuticals Corporation ($299.65) |
| 2022 | $1,991 | 130 | Novartis Pharmaceuticals Corporation ($248.50) |
| 2021 | $1,248 | 83 | Seagen Inc. ($143.54) |
| 2020 | $319.57 | 21 | E.R. Squibb & Sons, L.L.C. ($97.90) |
| 2019 | $622.44 | 47 | E.R. Squibb & Sons, L.L.C. ($121.21) |
| 2018 | $1,212 | 99 | Genentech USA, Inc. ($293.05) |
| 2017 | $1,038 | 103 | Novartis Pharmaceuticals Corporation ($248.12) |
All Payment Transactions
792 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.11 | General |
| Category: Hematology/Oncology | ||||||
| 12/15/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $17.70 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 12/12/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $9.87 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/02/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: Oncology | ||||||
| 11/26/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $9.75 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $22.06 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.22 | General |
| Category: Hematology | ||||||
| 11/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological), IMFINZI | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $67.51 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 767 | 16,439 | $2.0M | $286,814 |
| 2022 | 6 | 634 | 1,345 | $360,330 | $117,526 |
| 2021 | 7 | 684 | 1,792 | $451,241 | $196,886 |
| 2020 | 7 | 593 | 1,663 | $379,830 | $164,330 |
Total Patients
2,678
Total Services
21,239
Medicare Billing
$765,556
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 4,680 | $330,000 | $86,293 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 694 | $155,456 | $63,924 | 41.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 307 | $92,407 | $41,459 | 44.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 31 | 267 | $1.1M | $35,489 | 3.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 151 | $103,586 | $14,585 | 14.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 15 | 8,320 | $74,880 | $11,401 | 15.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 61 | 61 | $26,352 | $10,190 | 38.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 94 | 119 | $17,612 | $7,174 | 40.7% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 20 | 58 | $14,558 | $3,557 | 24.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 29 | 257 | $26,985 | $2,950 | 10.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 61 | $20,374 | $2,924 | 14.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 33 | 102 | $14,382 | $2,490 | 17.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 84 | $13,104 | $1,721 | 13.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 26 | 27 | $2,754 | $1,072 | 38.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 93 | $8,649 | $984.62 | 11.4% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 16 | 660 | $80,520 | $531.12 | 0.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 464 | $464.00 | $43.37 | 9.3% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 34 | $238.00 | $26.47 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 269 | 649 | $161,601 | $45,007 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 100 | 315 | $111,510 | $34,798 | 31.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 46 | 134 | $25,996 | $21,398 | 82.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 66 | 66 | $35,442 | $8,897 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 125 | 146 | $23,506 | $6,440 | 27.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 28 | 35 | $2,275 | $985.96 | 43.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 87 | 592 | $114,848 | $94,969 | 82.7% |
About Dr. David Snyder, MD
Dr. David Snyder, MD is a Medical Oncology healthcare provider based in Santa Fe, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1487653176.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Snyder, MD has received a total of $12,732 in payments from pharmaceutical and medical device companies, with $3,182 received in 2024. These payments were reported across 792 transactions from 65 companies. The most common payment nature is "Food and Beverage" ($12,588).
As a Medicare-enrolled provider, Snyder has provided services to 2,678 Medicare beneficiaries, totaling 21,239 services with total Medicare billing of $765,556. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Santa Fe, NM
- Active Since 07/15/2005
- Last Updated 06/02/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1487653176
Products in Payments
- KEYTRUDA (Biological) $527.79
- OPDIVO (Biological) $448.13
- Lenvima (Drug) $369.38
- KISQALI (Drug) $365.78
- CABOMETYX (Drug) $328.85
- Avastin (Biological) $288.87
- PROCLAIM (Device) $275.06
- JAKAFI (Drug) $263.74
- DARZALEX (Biological) $255.67
- XTANDI (Drug) $238.55
- BRUKINSA (Drug) $218.07
- ENHERTU (Biological) $207.77
- PLUVICTO (Drug) $193.91
- IMBRUVICA (Drug) $185.68
- Alecensa (Biological) $181.13
- PADCEV (Biological) $179.48
- VENCLEXTA (Drug) $173.33
- ADCETRIS (Biological) $166.36
- Stivarga (Drug) $164.38
- ERLEADA (Drug) $155.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.